p53: A potential target antigen for immunotherapy of cancer

Annals of the New York Academy of Sciences

Volumn 910, Issue , 2000, Pages 223-236

  Offringa, Rienk ^a   Vierboom, Michel P M ^a   Van Der Burg, Sjoerd H ^a   Erdile, Lorne ^b   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Virogenetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUTANT PROTEIN; PROTEIN P53; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE;

MURINAE;

EID: 0033943071     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06711.x     Document Type: Conference Paper

References (47)

1. 1. HOLLSTEIN, M., D. SIDRANSKY, B. VOGELSTEIN & C.C. HARRIS. 1991. p53 mutations in human cancers. Science 253: 49-53.
2. 2. MELIEF, C.J., R. OFFRINGA, R.E. TOES & W.M. KAST. 1996. Peptide-based cancer vaccines. Curr. Opin. Immunol. 8: 651-657.
3. 3. RESSING, M.E., R. OFFRINGA, R.E. TOES, F. OSSENDORP, J.H. DE JONG, R.M. BRANDT, W.M. KAST & C.J. MELIEF. 1996. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology 2: 241-251.
4. 4. VAN DEN EIJNDE, B. & P. VAN DER BRUGGEN. 1997. T cell-defined tumor antigens. Curr. Opin. Immunol. 9: 684-693.
5. 5. VAN ELSAS, A., A.A. HURWITZ & J.P. ALLISON. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366.
6. 6. ROGEL, A., M. POPLIKER, C.G. WEBB & M. OREN. 1985. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol. 5: 2851-2855.
7. 7. KUBBUTAT, M.H., S.N. JONES & K.H. VOUSDEN. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
8. 8. MAKI, C.G., J.M. HUIBREGTSE & P.M. HOWLEY. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56: 2649-2654.
9. 9. CIECHANOVER, A., J.A. DIGIUSEPPE, B. BERCOVICH, A. ORIAN, J.D. RICHTER, A.L. SCHWARTZ & G.M. BRODEUR. 1991. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Natl. Acad. Sci. USA 88: 139-143.
10. +T cells. Proc. Natl. Acad. Sci. USA 91: 3171-3175.
11. + cytotoxic T-cells. Cancer Res. 53: 3257-3261.
12. 12. HOUBIERS, J.G., H.W. NIJMAN, S.H. VAN DER BURG, J.W. DRIJFHOUT, P. KENEMANS, C.J. VAN DE VELDE, A. BRAND, F. MOMBURG, W.M. KAST & C.J. MELIEF. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077.
13. 13. VIERBOOM, M.P., H.W. NIJMAN, R. OFFRINGA, E.I. VAN DER VOORT, T. VAN HALL, L. VAN DEN BROEK, G.J. FLEUREN P. KENEMANS, W.M. KAST & C.J. MELIEF. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186: 695-704.
14. 14. VIERBOOM, M.P., S. ZWAVELING, G.M.J. BOS, M. OOMS, G.M. KRIETEMEYER, C.J.M. MELIEF & R. OFFRINGA. CTL specific for wild type p53 eradicate tumors expressing a wide range of p53 levels. Submitted for publication.
15. 15. ZANTEMA, A., P.I. SCHRIER, A. DAVIS-OLIVIER, T. VAN LAAR, R.T. VAESSEN & A.J. VAN DER EB. 1985. Adenovirus serotype determines association and localization of the large EIB tumor antigen with cellular tumor antigen p53 in transformed cells. Mol. Cell. Biol. 5: 3084-3091.
16. 16. SCHEFFNER, M., J.M. HUIBREGTSE, R.D. VIERSTRA & P.M. HOWLEY. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
17. 17. GNJATIC, S., Z. CAI, M. VIGUIER, S. CHOUAIB, J.G. GUILLET & J. CHOPPIN. 1998. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol. 160: 328-333.
18. 18. MAYORDOMO, J.I., D.J. LOFTUS, H. SAKAMOTO, C.M. DE CESARE, P.M. APPASAMY, M.T. LOTZE, W.J. STORKUS, E. APPELLA & A.B. DELEO. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183: 1357-1365.
19. 19. ROTH, J., D. DITTMER, D. REA, J. TARTAGLIA, E. PAOLETTI & A.J. LEVINE. 1996. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA 93: 4781-4786.
20. 20. HURPIN, C., C. ROTARIOA, H. BISCEGLIA, M. CHEVALIER, J. TARTAGLIA & L. ERDILE. 1998. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 16: 208-215.
21. 21. TUTING, T., A.B. DELEO, M.T. LOTZE & W.J. Storkus. 1997. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27: 2702-2707.
22. 22. THEOBALD, M., J. BIGGS, J. HERNANDEZ, J. LUSTGARTEN, C. LABADIE & L.A. SHERMAN. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841.
23. 23. ROSENBERG, S.A., J.C. YANG, D.J. SCHWARTZENTRUBER, P. HWU, F.M. MARINCOLA, S.L. TOPALIAN, N.P. RESTIFO, M.E. DUDLEY, S.L. SCHWARZ, P.J. SPIESS, J.R. WUNDERLICH, M.R. PARKHURST, Y. KAWAKAMI, C.A. SEIPP, J.H. EINHORN & D.E. WHITE. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4: 321-327.
24. 24. IRVINE, K.R., M.R. PARKHURST, E.P. SHULMAN, J.P. TUPESIS, M. CUSTER, C.E. TOULOUKIAN, P.F. ROBBINS, A.G. YAFAL, P. GREENHALGH, R.P. SUTMULLER, R. OFFRINGA, S.A. ROSENBERG & N.P. RESTIFO. 1999 Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res. 59: 2536-2540.
25. 25. STAUSS, H.J. 1999. Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today 20: 180-183.
26. 26. NIJMAN, H.W., S.H. VAN DER BURG, M.P. VIERBOOM, J.G. HOUBIERS, W.M. KAST & C.J. MELIEF. 1994. p53, a potential target for tumor-directed T cells. Immunol. Lett. 40: 171-178.
27. 27. ROPKE, M., J. HALD, P. GULDBERG, J. ZEUTHEN, L. NORGAARD, L. FUGGER, A. SVEJGAARD, S. VAN DER BURG, H.W. NIJMAN, C.J. MELIEF & M.H. CLAESSON. 1996. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93: 14704-14707.
28. 28. THEOBALD, M., T. RUPPERT, U. KUCKELKORN, J. HERNANDEZ A. HAUSSLER, E.A. FERREIRA, U. LIEWER, J. BIGGS, A.J. LEVINE, C. HUBER, U.H. KOSZINOWSKI, P.M. KLOETZEL & L.A. SHERMAN. 1998. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med. 188: 1017-1028.
29. 29. DELEO, A.B., G. JAY, E. APPELLA, G.C. DUBOIS, L.W. LAW & L.J. OLD. 1979. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76: 2420-2424.
30. 30. LUBIN, R., G. ZALCMAN, L. BOUCHET, J. TREDANEL, Y. LEGROS, D. CAZALS, A. HIRSCH & T. SOUSSI. 1995. Serum p53 antibodies as early markers of lung cancer. Nature Med. 1: 701-702.
31. 31. HOUBIERS, J.G., S.H. VAN DER BURG, L.M. VAN DE WATERING, R.A. TOLLENAAR, A. BRAND, C.J. VAN DE VELDE & C.J. MELIEF. 1995. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer 72: 637-641.
32. 32. VAN DER BURG, S.H., K. DE COCK, M. PALMEN, L. ERDILE, P. KUPPEN, C. VAN DER VELDE, C.J.M. MELIEF & R. OFFRINGA. T-helper immunity against defined p53-derived epitopes in colon cancer patients. Submitted for publication.
33. 33. TILKIN, A.F., R. LUBIN, T. SOUSSI, V. LAZAR, N. JANIN, M.C. MATHIEU, I. LEFRERE, C. CARLU, M. ROY, M. KAYIBANDA et al. 1995. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 25: 1765-1769.
34. + T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol. 28: 305-316.
35. 35. TOES, R.E., F. OSSENDORP, R. OFFRINGA & C.J. MELIEF. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189: 753-756.
36. 36. OSSENDORP, F., E. MENGEDE, M. CAMPS, R. FILIUS & C.J. MELIEF. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative rumors. J. Exp. Med. 187: 693-702.
37. 37. HUNG, K., R. HAYASHI, A. LAFOND-WALKER, C. LOWENSTEIN, D. PARDOLI. & H. LEVITSKY. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
38. 38. SCHOENBERGER, S.P., R.E. TOES, E.I. VAN DER VOORT, R. OFFRINGA & C.J. MELIEF. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
39. 39. BENNETT, S.R., F.R. CARBONE, F. KARAMALIS, R.A. FLAVELL, J.F. MILLER & W.R. HEATH. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
40. + T-helper and a T-killer cell. Nature 393: 474-478.
41. 41. SNIJDERS, A., P. KALINSKI, C.M. HILKENS & M.L. KAPSENBERG. 1998. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10: 1593-1598.
42. 42. REGNAULT, A., D. LANKAR, V. LACABANNE, A. RODRIGUEZ, C. THERY, M. RESCIGNO, T. SAITO, S. VERBEEK, C. BONNEROT, P. RICCIARDI-CASTAGNOLI & S. AMIGORENA. 1999. Fegamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189: 371-380.
43. 43. RUIZ, P.J., R. WOLKOWICZ, A. WAISMAN, D.L. HIRSCHBERG, P. CARMI, N. EREZ, H. GARREN, J. HERKEL, M. KARPUJ, L. STEINMAN, V. ROTTER & I.R. COHEN. 1999. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nature Med. 4: 710-712.
44. 44. QIN, Z., G. RICHTER, T. SCHULER, S. IBE, X. CAO & T. BLANKENSTEIN. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nature Med. 4:627-630.
45. 45. TSANG, K.Y., M. ZHU, C.A. NIERODA, P. CORREALE, S. ZAREMBA, J.M. HAMILTON, D. COLE, C. LAM & J. SCHLOM. 1997. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin. Cancer Res. 3: 2439-2449.
46. 46. HJELM SKOG, A., P. RAGNHAMMAR, J. FAGERBERG, J. FRODIN, M. GOLDINGER, H. KOLDESTAM, M. LILJEFORS, B. NILSSON, J. SHETYE, P. WERSALL & H. MELLSTEDT. 1999. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol. Immunother. 48: 463-470.
47. 47. HERLYN, D. & B. BIREBENT. 1999. Advances in cancer vaccine development. Ann. Med. 31:66-78.